Core Laboratories Inc. CLB
10.39
(0.10)
(0.95%)
as of 25 Sep
- Market cap
- $481.3M
- P/E
- 20.0×
Follow CLB
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
12.04% | 11.31% | 10.86% | 8.92% | |
| 5.39% | 5.08% | 4.92% | 4.10% | ||
ROIC |
9.36% | 9.81% | 9.19% | 8.08% | |
Return on Tangible Assets |
14.02% | 14.26% | 13.85% | 11.40% | |
Average Days of Receivables |
88.15 | 83.74 | 80.13 | 81.61 | |
Free Cash Flow per Share |
0.81 | 0.55 | 0.47 | 0.32 | |
Free Cash Flow |
37.55 | 25.33 | 21.59 | 14.64 | |
Capital Expenditures |
(12.15) | (11.70) | (12.74) | (13.59) | |
Piotroski F-Score |
5.00 | 6.00 | 7.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
11.92% | 9.14% | 8.33% | 6.79% | |
Accounts Receivable Turnover |
4.02 | 4.34 | 4.26 | 4.26 | |
Accounts Payable Turnover |
11.74 | 11.63 | 10.71 | 10.21 | |
Inventory Turnover |
6.70 | 7.33 | 7.19 | 7.10 | |
Average Days of Payables |
32.55 | 32.58 | 34.73 | 35.08 | |
Days of Inventory on Hand |
51.31 | 47.63 | 50.19 | 50.63 | |
Tax Rate |
(0.26) | (0.34) | (0.31) | (0.33) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
8.48% | 8.63% | 8.86% | 9.05% | |
Share Based Compensation of Revenue |
1.08% | 1.36% | 1.53% | 1.61% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.55 | 1.25 | 1.18 | 1.16 | |
Depreciation/Fixed assets |
0.15 | 0.15 | 0.15 | 0.15 | |
Capex/Depreciation |
(0.83) | (0.80) | (0.87) | (0.91) | |
Revenue per Share |
11.19 | 11.34 | 11.39 | 11.28 | |
Operating CF per Share |
1.07 | 0.80 | 0.75 | 0.61 | |
Capex per Share |
(0.26) | (0.25) | (0.28) | (0.30) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.03 | |
Net Profit Margin |
6.21% | 5.63% | 5.53% | 4.69% |
Columns are period end dates